Isaac Cheng is Director at Amylyx Pharmaceuticals, Inc. (AMLX). They have made 1 open-market trade across 1 company since 2022, most recently 2022-01-06.
CIK 0001829696
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $125K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AMLX | 7,819,999 | $206.1M |
Shares reported on the most recent Form 4, priced at the 2022-01-10 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AMLX | BUY | 2022-01-06 | 2022-01-10 | $19.00 | $125K | +12.2% | +24.8% | -23.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.